Medscint Receives Financial Support from Canada Economic Development
Québec City, November 10, 2025 — Medscint is proud to announce that it has received a repayable contribution of $400,000 from Canada Economic Development for Quebec Regions (CED) to accelerate the commercialization of its HYPERSCINT® optical dosimetry solutions for radiotherapy and support its expansion into international markets. On this occasion, Steeve Lavoie, Member of Parliament for Beauport–Limoilou, made the announcement in person at Medscint’s offices on behalf of the Honourable Mélanie Joly, Minister of Industry and Minister responsible for CED.

“SMEs play a central role in community development and are part of our government’s economic growth plan. By working with them, we are taking concrete steps to help strengthen their operations and their contribution to the regional economy. That is why I am delighted with the funding CED has granted to Medscint’s project, which will undeniably contribute to Québec’s economic vitality. Without a doubt, the success of this promising project will generate positive impacts across the region and throughout Quebec and Canada.”
Steeve Lavoie, Member of Parliament for Beauport–Limoilou
Medscint – A Québec-based Manufacturer Specializing in Optical Dosimetry for Radiotherapy

As a Québec-based manufacturer specializing in optical dosimetry for radiotherapy, Medscint focuses on innovation, collaboration, and local expertise to propel homegrown technology onto global markets.
“CED’s contribution represents strategic support to accelerate our mission: To make radiation therapy safer and more precise thanks to our optical dosimetry technology. This funding gives us the means to aim higher, by propelling our growth forward internationally and by showcasing Canadian innovation in the field of medical physics.”
François Therrriault-Proulx, PhD – CEO, President and Co-founder, Medscint
The Importance of Grants and Support: A Driver for Québec Innovation in Healthcare
In a sector as demanding as medical technology, the ability to innovate, validate clinically, and commercialize internationally relies heavily on strategic financial support. For Medscint, these resources have played a decisive role in achieving several major milestones. Thanks to grants and assistance programs obtained over the years, we have accelerated the development of our scintillation dosimetry solutions and ensured their adoption in clinical and preclinical environments. These resources also enabled us to launch the HYPERSCINT® QA solution, the result of years of research and collaborations with hospital partners, and to expand internationally with the delivery of our first solutions in Asia.
These achievements show that innovation goes far beyond the prototype: it must be tested, validated, industrialized, and exported. Programs like Canada Economic Development accelerate this transition from research to product, support the growth of skilled teams, and preserve scientific expertise in Canada. By promoting local medical solutions, these investments strengthen technological sovereignty and build a more resilient economy.
At Medscint, we view this public support as a fundamental lever for our mission. It gives us the means to innovate faster, export more widely, and showcase Québec’s expertise on the international stage, while supporting the scientific and clinical ecosystem that makes Canada renowned for cutting-edge medicine.
Follow us on social media: LinkedIn | Facebook | X